Avenanthramide pillGilles said it was avenanthramide's potential that attracted him to CZO originally. A CZO news release said the avenanthramide pill could be CZO's biggest product. Do we have a highly compelling treatment for exercise inflammation? The pill is up to 100X more potent than the exercise inflammation study. Once Gilles said he didn't like to discuss the size of the markets because they are so big. He talked about the $50 billion non-steroidal anti-inflammatory market and the significant share a new enterant can get even in its first year. He's talked about interest in COVID heart inflammation too. Dr. Tardif ran the largest outpatient COVID trial in the world with another anti-inflammatory and now he's in charge of AEZS's clinical trial. The first anti-inflammatory for heart disease was also recently approved by the FDA setting an important precedent and Dr. Tardif worked on that drug. While there is data from the human exercise inflammation study using a cookie and it was said to give line-of-sight concerning the development of a pharma-grade pill preclinical data for the pill has been marked top secret. We have never seen what they've managed to do with formulation to potentially enhance performance. Do we have a slow-release formulation for instance? Presenting such preclinical data supporting efficacy with first human data demonstrating safety/tolerability in the context of the history of avenanthramide research and human trials could be a significant moment. Preliminary efficacy data will also be generated in the current Phase I/IIa clinical trial. With the merger completed the company is now optimized to bring transformational products to market. What exactly do we have in this top secret pill? It has also been said that the company has worked with avenanthramide and its newer generation PGX carriers. Another group recently published yeast beta glucan-avenanthramide research. How could a PGX carrier further enhance avenanthramide strengthening its health benefits? PGX-YBG also has interesting anti-inflammatory properties and can have other benefits as in the CoQ10 study.
Perplexity Ai:
Based on the information provided, Corealis Pharma Inc. likely played a crucial role in developing the final tablet form of Ceapro's avenanthramide formulation. While specific details about Corealis Pharma's technology and IP are not mentioned, we can infer several potential contributions based on their expertise as a specialty pharmaceutical company: - Formulation optimization: Corealis Pharma likely used their expertise to optimize the tablet formulation, potentially improving factors like stability, dissolution rate, and bioavailability of the avenanthramide.
- Controlled release technology: As a specialty drug design company, Corealis may have applied controlled release technologies to the avenanthramide tablet, which could help maintain therapeutic levels of the active ingredient over time.
- Dosage form development: They likely assisted in developing the appropriate dosage form for the clinical trial, ensuring precise and consistent dosing across the range from 30 mg to 960 mg.
- Manufacturing process design: Corealis probably helped design a scalable manufacturing process for the tablets, which is crucial for clinical trials and potential future commercialization.
- Regulatory compliance: Their expertise likely ensured that the tablet formulation meets all necessary regulatory requirements for use in clinical trials.
- Stability testing: Corealis may have conducted stability studies to ensure the avenanthramide tablets remain effective throughout their shelf life.
- Analytical method development: They might have developed specific analytical methods for quality control and release testing of the final tablet formulation.
While the search results don't mention specific IP held by Corealis Pharma, it's possible they applied proprietary technologies or methods in the tablet development process. However, without more information, we can't confirm if any special IP was involved.The collaboration between Ceapro and Corealis Pharma appears to have been crucial in transitioning Ceapro's avenanthramide from a purified powder to a pharmaceutical-grade tablet suitable for clinical trials. This partnership likely combined Ceapro's expertise in avenanthramide production with Corealis Pharma's specialized knowledge in drug formulation and delivery systems.